Zealand to Raise $1B in Public Offering to Fund Obesity Candidates 6/26/2024

Curie.Bio Adds $380M Series A Fund to Move Biotech Startups to Clinic 6/26/2024

Lilly Teams With OpenAI to Tackle Threat of Drug-Resistant Bacteria 6/26/2024

Wave Clears Phase Ib/IIa Study in Huntington’s Disease, Eyes Accelerated Approval 6/26/2024

Teva Pays $750M to Resolve Israeli Tax Issues Going Back More Than a Decade 6/26/2024

How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs 6/26/2024

Sarepta’s Big DMD Approval, Alnylam’s Clinical Win and ADA Highlights 6/26/2024

After Full Approval, Sarepta Lays Out Its Next Moves 6/26/2024

Opinion: Prepare Your Biopharma for the Next Pandemic, for Business and Global Good 6/26/2024

Bayer AG, together with Charité - Universitätsmedizin Berlin, presented plans for the construction of the Berlin Center for Gene and Cell Therapies. The project is being substantially financed and supported by Germany's Federal Government as well as the State of Berlin. The aim of the joint project is to bring these groundbreaking technologies to patients more quickly while creating a leading biotech ecosystem for innovative therapies in Berlin.

A new AI-powered program will allow researchers to level up their drug discovery efforts.

The program, called TopoFormer, was developed by an interdisciplinary team led by Guowei Wei, a Michigan State University Research Foundation Professor in the Department of Mathematics. TopoFormer translates three-dimensional information about molecules into data that typical AI-based drug-interaction models can use, expanding those models' abilities to predict how effective a drug might be.

5 FDA Decisions to Watch in the Second Half of 2024 6/24/2024

FDA Action Alert: Merck, Verona, AbbVie and Rocket 6/24/2024

Each second of our lives, cells in our body grow and divide to ensure we stay healthy. However, this process has a dark side: if cell growth and divisions become excessive, that may cause cancer. To keep a safe balance, our cells are equipped with several molecular mechanisms to limit their own growth and division.

EMBL Hamburg's Wilmanns Group, in collaboration with research groups from the Center for Experimental Medicine Institute of Tumor Biology and the Martini Clinic at the University Medical Center Hamburg-Eppendorf (UKE), as well as the Leibniz Institute on Aging - Fritz Lipmann Institute, has revealed a new mechanism

Expanded Approval of Sarepta’s Elevidys Is Progress, But More Needed for DMD Patients 6/21/2024

Zealand Deepens Weight-Loss Portfolio With Strong Phase Ib Data for GLP-1 Alternative 6/21/2024

Jazz’s Tremor Drug Candidate Flops in Phase II Study, Misses Primary Endpoint 6/21/2024

Vertex Finally Reaches Pricing Deal with England’s NHS for Cystic Fibrosis Drug 6/21/2024

Vanda Turns Down Cycle, Future Pak Offers as Proposals ‘Undervalue’ Company 6/21/2024

Tectonic Completes Reverse Merger With Avrobio, Starts Trading on Nasdaq 6/21/2024